Filana Therapeutics
FLNA
25 hedge funds and large institutions have $2.55M invested in Filana Therapeutics in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 5 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
14.91% less ownership
Funds ownership: 32.3% → 17.39% (-15%)
54% less capital invested
Capital invested by funds: $5.58M → $2.55M (-$3.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$313K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$61.6K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$35.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$32.5K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$26.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.19M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$654K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$84.3K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$58K |
| 5 |
VF
Virtu Financial
New York
|
-$36.4K |
FLNA Hedge Fund Activity: Q4 2018 in Review
25 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q4 2018, worth a combined $2.55M — down 54% from $5.58M a quarter earlier.
Fund positioning in FLNA was balanced in Q4 2018: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $313K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.19M sold.
- 25 institutional investors held Filana Therapeutics (FLNA) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $2.55M of Filana Therapeutics stock for Q4 2018, down 54% quarter-over-quarter.
- 5 funds opened new Filana Therapeutics positions in Q4 2018 and 5 closed out, a net change of 0 holders.
- The largest Filana Therapeutics buyer in Q4 2018 was Renaissance Technologies, an estimated $313K added.
- The largest Filana Therapeutics seller in Q4 2018 was Armistice Capital, an estimated $2.19M sold.
Based on aggregated 13F filings for Q4 2018.